Company news

AC Immune SA news in 2024

AC Immune SA's news releases, calls and decks from 2024, newest first.

View company

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

December 9, 2024

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

November 13, 2024

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

November 12, 2024

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

November 4, 2024

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

September 16, 2024

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

August 27, 2024

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

August 5, 2024

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

July 30, 2024

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease

July 24, 2024

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

July 15, 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 27, 2024

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 12, 2024

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

May 12, 2024

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

March 13, 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

February 21, 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

January 21, 2024

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

January 2, 2024

Decks in 2024